2021 | Q1 Results

April 29, 2021

Introductory note

The performance analysis in this presentation is presented under IFRS16.

The Financial Statements excluding the effect of the IFRS16 are presented in the Appendix of this presentation.

2

INDEX

  1. 2021 Q1 HIGHLIGTHS
  2. 2021 Q1 | THE OPERATING CONTEXT
  3. KEY FIGURES
    1. Income Statement
    2. Cash Flow
    3. Balance Sheet
  4. SALES PERFORMANCE
    1. Group
    2. Biedronka
    3. Hebe
    4. Pingo Doce
    5. Recheio
    6. Ara
  1. EBITDA
    1. EBITDA Performance
    2. EBITDA Margin
  2. 2021 Q1 | SUMMARY

APPENDIX

  1. OUTLOOK 2021
  2. FINANCIAL STATEMENTS

3

0. 2021 Q1 | HIGHLIGHTS (1/2)

Sales up by 1.5%

(+5.7% in local

currencies)

EBITDA up

by 4.0%

(+8.9% in local

currencies)

Focus on growing sales by prioritising consumers and their needs drove strong sales delivery and allowed the capture of anticipated Easter benefit

EBITDA growth ahead of sales due to sound top line performance, good delivery from efficiency programmes and lower Covid-19 related costs

First quarter performance is difficult to read due to calendar effects related to Easter and the beginning of the pandemic crisis in March 2020

Nevertheless it is clear that all banners delivered well on key priorities

4

0. 2021 | HIGHLIGHTS (2/2)

Strong overall sales performance and good cost control driving sound start to the year Material negative FX impact

Q1 20

Q1 21

Net Sales & Services

4,715

+1.5%

4,786

(Excl. FX)

+5.7%

EBITDA

309

+4.0%

322

(Excl. FX)

+8.9%

EBITDA Margin

6.6%

6.7%

Net Earnings

35

+66.3%

58

(Excl. Other profits/losses)

38

+57.2%

59

EPS

0.06

0.09

(Excl. Other profits/losses)

0.06

0.09

Net Debt

2,064

1,768

Excl. Capitalized operating leases

-137

-491

5

Attachments

  • Original document
  • Permalink

Disclaimer

Jeronimo Martins SGPS SA published this content on 29 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 April 2021 08:12:08 UTC.